Enanta Pharmaceuticals Added to the NASDAQ Biotechnology Index

WATERTOWN, Mass.--()--Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that it was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). NASDAQ has announced that the annual re-ranking of the NASDAQ Biotechnology Index will become effective upon market open on December 22, 2014.

The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. For more information about the NASDAQ Biotechnology Index visit www.nasdaq.com.

About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs primarily in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of three direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin.

Contacts

Enanta Pharmaceuticals, Inc.
Investor Contact
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
MacDougall Biomedical Communications
Media Contact
Kari Watson, 781-235-3060
kwatson@macbiocom.com
or
Charles Liles, 781-235-3060
cliles@macbiocom.com

Recent Stories

RSS feed for Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.